Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRGNASDAQ:CINGOTCMKTS:CPMVNASDAQ:PMN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$1.71-3.1%$1.71$1.23▼$4.84$16.10M0.71392,290 shs98,900 shsCINGCingulate$3.87-8.9%$4.01$1.80▼$20.83$15.25M-0.881.08 million shs147,379 shsCPMVMosaic ImmunoEngineering$0.54$0.72$0.10▼$1.13$3.91M0.11969 shs4 shsPMNProMIS Neurosciences$0.53+5.0%$0.63$0.47▼$2.37$17.33M0.0275,558 shs14,848 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI-8.07%+3.22%-1.40%-55.43%-39.97%CINGCingulate+8.70%+8.42%+5.72%-2.07%+424.69%CPMVMosaic ImmunoEngineering0.00%-27.81%-13.88%-46.00%+35.00%PMNProMIS Neurosciences-2.88%-9.74%-12.08%-47.23%-74.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRGBullfrog AI1.1984 of 5 stars0.04.00.00.03.12.50.0CINGCingulate2.0187 of 5 stars3.62.00.00.02.20.80.6CPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences1.9411 of 5 stars3.52.00.00.02.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 0.00N/AN/AN/ACINGCingulate 3.20Buy$30.67692.42% UpsideCPMVMosaic ImmunoEngineering 0.00N/AN/AN/APMNProMIS Neurosciences 3.00Buy$4.50749.06% UpsideCurrent Analyst Ratings BreakdownLatest CPMV, BFRG, PMN, and CING Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025PMNProMIS NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.004/1/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/6/2025CINGCingulateHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.002/26/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$60K268.33N/AN/A$0.43 per share3.98CINGCingulateN/AN/AN/AN/A($70.63) per shareN/ACPMVMosaic ImmunoEngineeringN/AN/AN/AN/A($0.81) per shareN/APMNProMIS NeurosciencesN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$5.36M-$0.86N/A∞N/AN/A-141.39%-124.63%N/ACINGCingulate-$23.53M-$8.48N/AN/AN/AN/A-570.20%-236.15%N/ACPMVMosaic ImmunoEngineering-$1.01M-$0.13N/A∞N/AN/AN/A-1,371.05%5/15/2025 (Estimated)PMNProMIS Neurosciences-$13.21M-$0.03N/AN/AN/AN/A-636.20%-130.32%N/ALatest CPMV, BFRG, PMN, and CING EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/A5/12/2025Q1 2025PMNProMIS Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/A4/15/2025Q4 2024CPMVMosaic ImmunoEngineeringN/A-$0.02N/A-$0.02N/AN/A3/31/2025Q4 2024PMNProMIS Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/A3/14/2025Q4 2024BFRGBullfrog AIN/A-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ACPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A5.905.90CINGCingulateN/A7.357.35CPMVMosaic ImmunoEngineeringN/A0.010.01PMNProMIS NeurosciencesN/A9.309.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%CINGCingulate41.31%CPMVMosaic ImmunoEngineeringN/APMNProMIS Neurosciences50.13%Insider OwnershipCompanyInsider OwnershipBFRGBullfrog AI33.90%CINGCingulate5.27%CPMVMosaic ImmunoEngineering80.99%PMNProMIS Neurosciences4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI49.42 million5.76 millionNot OptionableCINGCingulate203.94 million2.66 millionNot OptionableCPMVMosaic ImmunoEngineering37.24 million1.38 millionNot OptionablePMNProMIS Neurosciences532.69 million31.25 millionNot OptionableCPMV, BFRG, PMN, and CING HeadlinesRecent News About These CompaniesMaxim Group Initiates Coverage on ProMIS Neurosciences (NASDAQ:PMN)May 14 at 1:57 AM | americanbankingnews.comProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's DiseaseMay 13 at 8:14 PM | nasdaq.comProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | BenzingaMay 13 at 4:19 AM | benzinga.comProMIS Neurosciences Announces First Quarter 2025 Financial ResultsMay 12 at 7:30 AM | globenewswire.comProMIS Neurosciences (PMN) Projected to Post Quarterly Earnings on TuesdayMay 12 at 4:03 AM | americanbankingnews.comProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last yearMarch 31, 2025 | markets.businessinsider.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | finanznachrichten.deProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent HighlightsMarch 31, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International ConferenceMarch 24, 2025 | globenewswire.comProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual MeetingMarch 13, 2025 | globenewswire.comProMIS Neurosciences to Participate in the 37th Annual Roth ConferenceMarch 11, 2025 | globenewswire.comProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s DiseaseFebruary 25, 2025 | markets.businessinsider.comProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trialFebruary 25, 2025 | markets.businessinsider.comProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's DiseaseFebruary 25, 2025 | globenewswire.comProMIS Neurosciences Separates With Gavin T. Malenfant as Chief Operating OfficerFebruary 20, 2025 | marketwatch.comProMIS Neurosciences seperates from COO Malenfant, terminates COO positionFebruary 20, 2025 | markets.businessinsider.comProMIS Neurosciences, Inc. (NASDAQ:PMN) Insider Neil Cashman Acquires 15,000 SharesFebruary 13, 2025 | insidertrades.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | financialpost.comProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPMV, BFRG, PMN, and CING Company DescriptionsBullfrog AI NASDAQ:BFRG$1.71 -0.06 (-3.12%) As of 04:00 PM EasternBullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Cingulate NASDAQ:CING$3.87 -0.38 (-8.94%) As of 04:00 PM EasternCingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Mosaic ImmunoEngineering OTCMKTS:CPMV$0.54 0.00 (0.00%) As of 05/14/2025Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.ProMIS Neurosciences NASDAQ:PMN$0.53 +0.03 (+4.95%) As of 03:30 PM EasternProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
